AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9649988 — intervention group
Group type: EXPERIMENTAL
Intervention: PCA group received a continuous infusion of 1.5 mg h‐1 piritramide
Number of subjects: 20
Study 9649988 — intervention group
Group type: COMPARATOR
Intervention: i.m. group received 0.3 mg kg‐1 piritramide i.m. when requested by the patient
Number of subjects: 20
Study 7588182 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressants (imipramine)
Number of subjects: 0
Study 7588182 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 3338367 — intervention group
Group type: EXPERIMENTAL
Intervention: Golytely supplemented with simethicone
Number of subjects: 0
Study 3338367 — intervention group
Group type: COMPARATOR
Intervention: Golytely alone
Number of subjects: 0
Study 31553463 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopy-Assisted Distal Gastrectomy (LADG) with D2 lymphadenectomy
Number of subjects: 96
Study 31553463 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopy-Assisted Distal Gastrectomy (LADG)
Number of subjects: 96
Study 31553463 — intervention group
Group type: COMPARATOR
Intervention: Open Distal Gastrectomy (ODG) with D2 lymphadenectomy
Number of subjects: 96
Study 31553463 — intervention group
Group type: COMPARATOR
Intervention: Open Distal Gastrectomy (ODG)
Number of subjects: 96
Study 28434056 — intervention group
Group type: COMPARATOR
Intervention: Behavioral intervention targeting maternal alcohol use, malnutrition, and HIV, specific dosage and duration not available
Number of subjects: 0
Study 21878465 — intervention group
Group type: EXPERIMENTAL
Intervention: Office ergonomic training
Number of subjects: 6
Study 21878465 — intervention group
Group type: COMPARATOR
Intervention: Leaflet (Control)
Number of subjects: 6
Study 22562070 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional first aid training plus supplementary training to reduce barriers to helping
Number of subjects: 72
Study 22562070 — intervention group
Group type: COMPARATOR
Intervention: Conventional first aid training (control group)
Number of subjects: 72
Study 21620064 — intervention group
Group type: EXPERIMENTAL
Intervention: Contemporaneous portal and hepatic artery revascularization (CPAr)
Number of subjects: 40
Study 21620064 — intervention group
Group type: COMPARATOR
Intervention: Sequential portal and arterial revascularization (SPAr)
Number of subjects: 40
Study 19336538 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil with sevoflurane end‐tidal concentration of 2.5%
Number of subjects: 63
Study 19336538 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil with sevoflurane end‐tidal concentration of 3%
Number of subjects: 63
Study 19336538 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil with sevoflurane end‐tidal concentration of 3.5%
Number of subjects: 63
Study 17059015 — intervention group
Group type: EXPERIMENTAL
Intervention: Four-step therapeutics of Traditional Chinese Medicine (TCM)
Number of subjects: 120
Study 17059015 — intervention group
Group type: COMPARATOR
Intervention: 100mg Lamivudine orally daily for two years (Control)
Number of subjects: 120
Study 17059015 — intervention group
Group type: EXPERIMENTAL
Intervention: Four-step therapeutics of TCM
Number of subjects: 120
Study 15546231 — intervention group
Group type: EXPERIMENTAL
Intervention: Distraction during recovery
Number of subjects: 80
Study 15546231 — intervention group
Group type: EXPERIMENTAL
Intervention: Hostility
Number of subjects: 80
Study 15546231 — intervention group
Group type: COMPARATOR
Intervention: Control group (no distraction)
Number of subjects: 80
Study 10908991 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment with Meniett apparatus
Number of subjects: 56
Study 10908991 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 56
Study 9077718 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg lansoprazole
Number of subjects: 17
Study 9077718 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg lansoprazole
Number of subjects: 17
Study 9077718 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg omeprazole
Number of subjects: 17
Study 8113660 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 mg of prostaglandin E2 in 3 ml of gel intracervically
Number of subjects: 48
Study 8113660 — intervention group
Group type: COMPARATOR
Intervention: 3 mg prostaglandin E2 tablet intravaginally
Number of subjects: 48
Study 8113660 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracervical route
Number of subjects: 48
Study 8113660 — intervention group
Group type: COMPARATOR
Intervention: Intravaginal route
Number of subjects: 48
Study 3295034 — intervention group
Group type: EXPERIMENTAL
Intervention: slow-potassium (72 mmol/day)
Number of subjects: 40
Study 3295034 — intervention group
Group type: COMPARATOR
Intervention: slow-sodium (90 mmol/day)
Number of subjects: 40
Study 3295034 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 40
Study 3295034 — intervention group
Group type: EXPERIMENTAL
Intervention: low sodium/high potassium diet
Number of subjects: 40
Study 3295034 — intervention group
Group type: COMPARATOR
Intervention: sodium restriction alone
Number of subjects: 40
Study 31618456 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced-dose plerixafor (0.12 mg/kg) plus filgrastim (10 μg/kg/4 days)
Number of subjects: 20
Study 27989565 — intervention group
Group type: EXPERIMENTAL
Intervention: Wearable technology to track bite portions
Number of subjects: 0
Study 27989565 — intervention group
Group type: COMPARATOR
Intervention: Mental tracking of food intake
Number of subjects: 0
Study 26572609 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein-rich nutritional supplementation (40g of protein and 600 kcal daily for six months) and bisphosphonates (once weekly for 12 months)
Number of subjects: 79
Study 26572609 — intervention group
Group type: COMPARATOR
Intervention: Bisphosphonates alone (once weekly for 12 months)
Number of subjects: 79
Study 26572609 — intervention group
Group type: COMPARATOR
Intervention: Calcium (1g daily) and vitamin D3 (800 IU daily)
Number of subjects: 79
Study 26572609 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional supplementation (Protein-rich)
Number of subjects: 79
Study 23546559 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrous oxide (N2O) by inhalation
Number of subjects: 450
Study 23546559 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep sedation (intravenous mixture of midazolam, remifentanil, and propofol)
Number of subjects: 450
Study 23546559 — intervention group
Group type: COMPARATOR
Intervention: No sedation
Number of subjects: 450
Study 21334008 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal thoracic artery grafting
Number of subjects: 3087
Study 19630726 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 0
Study 19630726 — intervention group
Group type: EXPERIMENTAL
Intervention: Nalmefene
Number of subjects: 0
Study 19630726 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone depot
Number of subjects: 0
Study 20143498 — intervention group
Group type: EXPERIMENTAL
Intervention: Caucasian/European Americans
Number of subjects: 2221
Study 20143498 — intervention group
Group type: EXPERIMENTAL
Intervention: Black/African‐Americans
Number of subjects: 2221
Study 20143498 — intervention group
Group type: EXPERIMENTAL
Intervention: Hispanic/Latino‐Americans
Number of subjects: 2221
Study 20143498 — intervention group
Group type: EXPERIMENTAL
Intervention: Asian‐Americans
Number of subjects: 2221
Study 20143498 — intervention group
Group type: EXPERIMENTAL
Intervention: Others
Number of subjects: 2221
Study 20143498 — intervention group
Group type: EXPERIMENTAL
Intervention: Unknown
Number of subjects: 2221
Study 15679750 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid detoxification with general anaesthesia (RD-GA)
Number of subjects: 272
Study 15679750 — intervention group
Group type: COMPARATOR
Intervention: Rapid detoxification without general anaesthesia (RD)
Number of subjects: 272
Study 12168912 — intervention group
Group type: EXPERIMENTAL
Intervention: Taxotere plus bromocriptine
Number of subjects: 30
Study 12168912 — intervention group
Group type: COMPARATOR
Intervention: Taxotere alone
Number of subjects: 30
Study 9722274 — intervention group
Group type: EXPERIMENTAL
Intervention: Amorphous calcium phosphate
Number of subjects: 38
Study 9722274 — intervention group
Group type: COMPARATOR
Intervention: Control (water solution)
Number of subjects: 38
Study 7989852 — intervention group
Group type: EXPERIMENTAL
Intervention: Homework policy instituted
Number of subjects: 550
Study 7989852 — intervention group
Group type: EXPERIMENTAL
Intervention: Modifications for students with disabilities
Number of subjects: 550
Study 7989852 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequency and amount of homework assigned
Number of subjects: 550
Study 7989852 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-school communication mechanisms
Number of subjects: 550
Study 2730998 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate (300 mg/kg body weight)
Number of subjects: 23
Study 2730998 — intervention group
Group type: COMPARATOR
Intervention: Placebo (8 g sodium chloride)
Number of subjects: 23
Study 1101842 — intervention group
Group type: EXPERIMENTAL
Intervention: Very high dose fluphenazine (1,200 mg/day)
Number of subjects: 31
Study 1101842 — intervention group
Group type: COMPARATOR
Intervention: Standard dose fluphenazine
Number of subjects: 31
Study 31951771 — intervention group
Group type: EXPERIMENTAL
Intervention: RTS,S/AS01E
Number of subjects: 100
Study 31951771 — intervention group
Group type: COMPARATOR
Intervention: HepB control vaccine
Number of subjects: 100
Study 31849356 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-layer continuous sutures (group I)
Number of subjects: 103
Study 31849356 — intervention group
Group type: COMPARATOR
Intervention: Two-layer interrupted sutures (group II)
Number of subjects: 103
Study 30013091 — intervention group
Group type: EXPERIMENTAL
Intervention: Panitumumab
Number of subjects: 559
Study 30013091 — intervention group
Group type: COMPARATOR
Intervention: Comparator
Number of subjects: 559
Study 29798042 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryotherapy
Number of subjects: 68
Study 29798042 — intervention group
Group type: COMPARATOR
Intervention: Traditional separation surgery
Number of subjects: 68
Study 24697345 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacological treatment combined with bladder training (n = 440)
Number of subjects: 845
Study 24697345 — intervention group
Group type: COMPARATOR
Intervention: Pharmacological treatment alone (n = 405)
Number of subjects: 845
Study 21843001 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV risk-reduction intervention
Number of subjects: 715
Study 19887347 — intervention group
Group type: EXPERIMENTAL
Intervention: Kefir
Number of subjects: 40
Study 19887347 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 40
Study 17178774 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric exercises with a night splint (night splint group, n = 36)
Number of subjects: 70
Study 17178774 — intervention group
Group type: COMPARATOR
Intervention: Eccentric exercises only (eccentric group, n = 34)
Number of subjects: 70
Study 14970839 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcoholic red wine
Number of subjects: 8
Study 14970839 — intervention group
Group type: EXPERIMENTAL
Intervention: Dealcoholized red wine
Number of subjects: 8
Study 14970839 — intervention group
Group type: COMPARATOR
Intervention: Water
Number of subjects: 8
Study 11567937 — intervention group
Group type: EXPERIMENTAL
Intervention: Solar disinfection of drinking water
Number of subjects: 299
Study 11567937 — intervention group
Group type: COMPARATOR
Intervention: Control (water kept indoors)
Number of subjects: 299
Study 9543139 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormonal contraception
Number of subjects: 19
Study 9543139 — intervention group
Group type: COMPARATOR
Intervention: Regular menstrual cycle
Number of subjects: 19
Study 9543139 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 19
Study 8059074 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (5 mg/kg)
Number of subjects: 6
Study 8059074 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 6
Study 3195646 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative perfluorocarbon liquids
Number of subjects: 23
Study 29354930 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin needle embedding therapy
Number of subjects: 300
Study 27631719 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care plus dietitian-delivered DASH-based dietary counselling in a single one-to-one session (n=281)
Number of subjects: 556
Study 27631719 — intervention group
Group type: COMPARATOR
Intervention: Standard education (usual care) (n=275)
Number of subjects: 556
Study 26586732 — intervention group
Group type: EXPERIMENTAL
Intervention: Alirocumab 150 mg every 2 weeks
Number of subjects: 57
Study 26586732 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study 23444204 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid
Number of subjects: 40
Study 23444204 — intervention group
Group type: COMPARATOR
Intervention: Open flap debridement
Number of subjects: 40
Study 19880189 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine, venlafaxine, or venlafaxine plus quetiapine during follow-up
Number of subjects: 59
Study 18928105 — intervention group
Group type: EXPERIMENTAL
Intervention: Sanhuang Yilong Decoction (SYD)
Number of subjects: 90
Study 18928105 — intervention group
Group type: COMPARATOR
Intervention: Non-steroid anti-inflammatory drugs
Number of subjects: 90
Study 17064543 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbar surgery for patients with degenerative knee joints
Number of subjects: 237
Study 17064543 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbar surgery for patients with degenerative hip joints
Number of subjects: 237
Study 17064543 — intervention group
Group type: COMPARATOR
Intervention: Control group (160 patients with lower extremity joint pain and negative physical examination)
Number of subjects: 237
Study 12373475 — intervention group
Group type: EXPERIMENTAL
Intervention: Early surfactant administration (Curosurf at a dose of 100 mg/kg as a single bolus via the endotracheal tube within 1 min after intubation)
Number of subjects: 43
Study 12373475 — intervention group
Group type: EXPERIMENTAL
Intervention: Early surfactant administration
Number of subjects: 43
Study 12373475 — intervention group
Group type: COMPARATOR
Intervention: Delayed surfactant administration (during HFOV only when defined criteria were reached)
Number of subjects: 43
Study 12373475 — intervention group
Group type: COMPARATOR
Intervention: Delayed surfactant administration
Number of subjects: 43
Study 10407204 — intervention group
Group type: EXPERIMENTAL
Intervention: Incongruent trials
Number of subjects: 0
Study 10407204 — intervention group
Group type: COMPARATOR
Intervention: Congruent, neutral, or word identification trials
Number of subjects: 0
Study 7760659 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortisporin Otic Suspension (COS; 0.5 mL)
Number of subjects: 50
Study 7760659 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated ear)
Number of subjects: 50
Study 2081608 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (80-160 mg per day)
Number of subjects: 30
Study 2081608 — intervention group
Group type: COMPARATOR
Intervention: Acebutolol (400-800 mg per day)
Number of subjects: 30
Study 115039 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlordiazepoxide
Number of subjects: 22
Study 115039 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 29461121 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 3% tranexamic acid combined with 1064-nm QSNYL laser
Number of subjects: 25
Study 29461121 — intervention group
Group type: COMPARATOR
Intervention: Vehicle treatment (control)
Number of subjects: 25
Study 26514079 — intervention group
Group type: EXPERIMENTAL
Intervention: ICT-guided-DMS
Number of subjects: 179
Study 26514079 — intervention group
Group type: COMPARATOR
Intervention: ICT-guided-DMS + telemonitoring
Number of subjects: 179
Study 26514079 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 179
Study 25123170 — intervention group
Group type: EXPERIMENTAL
Intervention: Three daily servings of dairy products
Number of subjects: 89
Study 25123170 — intervention group
Group type: COMPARATOR
Intervention: Control products equivalent in macronutrients and sodium
Number of subjects: 89
Study 23505165 — intervention group
Group type: EXPERIMENTAL
Intervention: Facebook Plus text messaging and personalized feedback
Number of subjects: 52
Study 23505165 — intervention group
Group type: EXPERIMENTAL
Intervention: Facebook
Number of subjects: 52
Study 23505165 — intervention group
Group type: COMPARATOR
Intervention: Waiting List control
Number of subjects: 52
Study 20500135 — intervention group
Group type: EXPERIMENTAL
Intervention: Conical-PEP breathing with a positive expiratory pressure of 4-20 cmH2O during exercise
Number of subjects: 13
Study 20500135 — intervention group
Group type: COMPARATOR
Intervention: Normal breathing
Number of subjects: 13
Study 18688814 — intervention group
Group type: EXPERIMENTAL
Intervention: B. macrostemi plus baseline therapy
Number of subjects: 79
Study 18688814 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus baseline therapy
Number of subjects: 79
Study 16367880 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone 15 mg
Number of subjects: 88
Study 16367880 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone 30 mg
Number of subjects: 88
Study 16367880 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone 45 mg
Number of subjects: 88
Study 16367880 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone (15, 30, and 45 mg)
Number of subjects: 88
Study 16367880 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study 14669295 — intervention group
Group type: EXPERIMENTAL
Intervention: Music therapy
Number of subjects: 69
Study 14669295 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 69
Study 10762100 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage-mismatched intervention (action-oriented activities)
Number of subjects: 92
Study 10762100 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage-matched intervention (think more about quitting)
Number of subjects: 92
Study 10762100 — intervention group
Group type: COMPARATOR
Intervention: No-intervention condition
Number of subjects: 92
Study 9266880 — intervention group
Group type: EXPERIMENTAL
Intervention: Bleomycin
Number of subjects: 35
Study 9266880 — intervention group
Group type: EXPERIMENTAL
Intervention: Talc slurry
Number of subjects: 35
Study 9266880 — intervention group
Group type: COMPARATOR
Intervention: Both treatments
Number of subjects: 35
Study 8290682 — intervention group
Group type: EXPERIMENTAL
Intervention: Nortriptyline (NT)
Number of subjects: 72
Study 8290682 — intervention group
Group type: COMPARATOR
Intervention: Bethanechol (placebo-controlled trial)
Number of subjects: 72
Study 3559982 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine (7.5, 15, and 30 mg)
Number of subjects: 15
Study 3559982 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentazocine (22.5, 45, and 90 mg)
Number of subjects: 15
Study 3559982 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciramadol (30, 60, and 120 mg)
Number of subjects: 15
Study 3559982 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 29171112 — intervention group
Group type: EXPERIMENTAL
Intervention: BeWEL intervention (diet and activity programme)
Number of subjects: 163
Study 27134057 — intervention group
Group type: EXPERIMENTAL
Intervention: Short DAPT (≤6 months)
Number of subjects: 18810
Study 27134057 — intervention group
Group type: COMPARATOR
Intervention: Long DAPT (≥12 months)
Number of subjects: 18810
Study 24588606 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotion Enhanced Triple P (EETP)
Number of subjects: 36
Study 24588606 — intervention group
Group type: COMPARATOR
Intervention: Group Triple P (GTP)
Number of subjects: 36
Study 22298568 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral tocotrienols (200 mg mixed tocotrienols, b.i.d.)
Number of subjects: 80
Study 22298568 — intervention group
Group type: COMPARATOR
Intervention: Oral tocopherols (200 mg α‐tocopherol, b.i.d.)
Number of subjects: 80
Study 20102300 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor (G-CSF) therapy
Number of subjects: 72
Study 20102300 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 18245019 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabotropic glutamate receptor agonists
Number of subjects: 0
Study 18245019 — intervention group
Group type: COMPARATOR
Intervention: Dopamine receptor‐blocking drugs
Number of subjects: 0
Study 15914552 — intervention group
Group type: EXPERIMENTAL
Intervention: R-CHOP (375 mg/m2 rituximab with each chemotherapy cycle, n = 99)
Number of subjects: 150
Study 15914552 — intervention group
Group type: COMPARATOR
Intervention: CHOP (no immunotherapy, n = 50)
Number of subjects: 150
Study 15914552 — intervention group
Group type: EXPERIMENTAL
Intervention: R-CHOP
Number of subjects: 150
Study 15914552 — intervention group
Group type: COMPARATOR
Intervention: CHOP
Number of subjects: 150
Study 12199261 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimetazidine
Number of subjects: 0
Study 12199261 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9885074 — intervention group
Group type: EXPERIMENTAL
Intervention: Tactile discrimination testing in German subjects
Number of subjects: 0
Study 9885074 — intervention group
Group type: EXPERIMENTAL
Intervention: Tactile discrimination testing in Kenyan Masai shepherds
Number of subjects: 0
Study 7703929 — intervention group
Group type: COMPARATOR
Intervention: Ampho‐B/G (1 mg/kg)
Number of subjects: 24
Study 7703929 — intervention group
Group type: EXPERIMENTAL
Intervention: Ampho‐B/Lipid (1 mg/kg)
Number of subjects: 24
Study 7703929 — intervention group
Group type: EXPERIMENTAL
Intervention: AmBisome (3 mg/kg)
Number of subjects: 24
Study 2650734 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate:fat ratio of 2.64
Number of subjects: 0
Study 2650734 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate:fat ratio of 0.50
Number of subjects: 0
Study 2650734 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher carbohydrate:fat ratios
Number of subjects: 0
Study 2650734 — intervention group
Group type: EXPERIMENTAL
Intervention: All four meals
Number of subjects: 0
Study 4348475 — intervention group
Group type: EXPERIMENTAL
Intervention: P1496, a new non-steroidal oestrogen analogue
Number of subjects: 0